Literature DB >> 18056265

Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.

Radhika V Korupolu1, Uwe Muenster, Jessica D Read, Wylie Vale, Wolfgang H Fischer.   

Abstract

Activins and bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta family of growth and differentiation factors that induce signaling in target cells by assembling type II and type I receptors at the cell surface. Ligand residues involved in type II binding are located predominantly in the C-terminal region that forms an extended beta-sheet, whereas residues involved in type I binding are located in the alpha-helical and preceding loop central portion of the molecule. To test whether the central residues are sufficient to determine specificity toward type I receptors, activin A/BMP chimeras were constructed in which the central residues (45-79) of activin A were replaced with corresponding residues of BMP2 and BMP7. The chimeras were assessed for activin type II receptor (Act RII) binding, activin-like bioactivity, and BMP-like activity as well as antagonistic properties toward activin A and myostatin. ActA/BMP7 chimera retained Act RII binding affinity comparable with wild type activin A, whereas ActA/BMP2 chimera showed a slightly reduced affinity toward Act RII. Both the chimeras were devoid of significant activin bioactivity in 293T cells in the A3 Lux reporter assay up to concentrations 10-fold higher than the minimal effective activin A concentration (approximately 4 nM). In contrast, these chimeras showed BMP-like activity in a BRE-Luc assay in HepG2 cells as well as induced osteoblast-like phenotype in C2C12 cells expressing alkaline phosphatase. Furthermore, both the chimeras activated Smad1 but not Smad2 in C2C12 cells. Also, both the chimeras antagonized ligands that signal via activin type II receptor, such as activin A and myostatin. These data indicate that activin residues in the central region determine its specificity toward type I receptors. ActA/BMP chimeras can be useful in the study of receptor specificities and modulation of transforming growth factor-beta members, activins, and BMPs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056265     DOI: 10.1074/jbc.M704530200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.

Authors:  Jennifer C Carr; Fadi S Dahdaleh; Donghong Wang; James R Howe
Journal:  J Surg Res       Date:  2011-11-30       Impact factor: 2.192

2.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

Review 3.  Antagonism of activin by activin chimeras.

Authors:  Uwe Muenster; Radhika Korupolu; Ratindra Rastogi; Jessica Read; Wolfgang H Fischer
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

Review 4.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

5.  The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Authors:  Robin Stamler; Henry T Keutmann; Yisrael Sidis; Chandramohan Kattamuri; Alan Schneyer; Thomas B Thompson
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

6.  The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Authors:  Jennifer N Cash; Carlis A Rejon; Alexandra C McPherron; Daniel J Bernard; Thomas B Thompson
Journal:  EMBO J       Date:  2009-07-30       Impact factor: 11.598

7.  Activin A/BMP2 chimera AB235 drives efficient redifferentiation of long term cultured autologous chondrocytes.

Authors:  G Jiménez; E López-Ruiz; W Kwiatkowski; E Montañez; F Arrebola; E Carrillo; P C Gray; J C Izpisua Belmonte; S Choe; M Perán; J A Marchal
Journal:  Sci Rep       Date:  2015-11-13       Impact factor: 4.379

8.  Relative abundance of mature myostatin rather than total myostatin is negatively associated with bone mineral density in Chinese.

Authors:  Long-Fei Wu; Dong-Cheng Zhu; Bing-Hua Wang; Yi-Hua Lu; Pei He; Yun-Hong Zhang; Hong-Qin Gao; Xiao-Wei Zhu; Wei Xia; Hong Zhu; Xing-Bo Mo; Xin Lu; Lei Zhang; Yong-Hong Zhang; Fei-Yan Deng; Shu-Feng Lei
Journal:  J Cell Mol Med       Date:  2017-12-16       Impact factor: 5.310

9.  Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop.

Authors:  Senem Aykul; Richard A Corpina; Erich J Goebel; Camille J Cunanan; Alexandra Dimitriou; Hyon Jong Kim; Qian Zhang; Ashique Rafique; Raymond Leidich; Xin Wang; Joyce McClain; Johanna Jimenez; Kalyan C Nannuru; Nyanza J Rothman; John B Lees-Shepard; Erik Martinez-Hackert; Andrew J Murphy; Thomas B Thompson; Aris N Economides; Vincent Idone
Journal:  Elife       Date:  2020-06-09       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.